Shenzhen Kangtai Biological Products' high P/S ratio seems irrational due to the dismal revenue projections. Optimistic investors expecting a business revival might be let down if the P/S ratio syncs with growth forecasts. The stock could be overinflated and may bear the risk of falling significantly.